Fig. 3From: Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patientsKaplan–Meier curves for progression-free survival (PFS) in A) the FL group, patients receiving first-line treatment with bevacizumab; B the three subgroups of the FL groupBack to article page